---
title: Case Study in Lipid-based Nanoparticle Carrier Applications
description: A Formulation Forum column penned by Ascendia CEO Jim Huang, Ph.D., discussed a case study in lipid-based nano-particle carrier applications. Read more.
---

[Pharmaceutical Industry Blog - Ascendia Pharmaceutical Solutions Blog ](https://ascendiacdmo.com/newsroom)

# [Case Study in Lipid-based Nanoparticle Carrier Applications](https://ascendiacdmo.com/newsroom/2020/12/09/case-study-in-lipid-based-nanoparticle-carrier-applications)

 Written by [Patrick Brightman](https://ascendiacdmo.com/newsroom/author/patrick-brightman) | Dec 9, 2020 5:00:00 AM

A recent Formulation Forum column penned by Ascendia Founder and CEO Jim Huang, PhD, discussed how lipid-based colloidal nanocarriers administered by a parenteral route hold great promise in safely delivering therapeutic agents. The [article](https://drug-dev.com/formulation-forum-parenteral-sustained-delivery-of-asd-005-liposomal-formulation-a-case-study-in-applications-of-lipid-based-nanoparticle-carriers/) was published on *Drug Development & Delivery*, a leading trade media property.

The guest editorial explains that the promise is due to lipid-based colloidal nanocarriers’ advantageous properties with respect to having excellent biocompatibility, potential for sustained drug delivery, ability to encapsulate hydrophilic and hydrophobic drugs, and site-specific active or passive targeting. Examples of lipid-based dosage forms include liposomes, lipoplexes, solid lipid nanoparticles, and nano-structure lipid carriers.

The opinion was supported by a study of parenteral sustained delivery of ASD-005 liposomal formulation. The study showed encapsulation of ASD-005 into a liposomal formulation with a nano-size range of 100 nm to 150 nm and with good physical stability. A differential scanning calorimeter (DSC) thermogram indicated that ASD-005 is present inside the liposomal formulation as an amorphous form.

The study indicated that parenteral administration of liposomal ASD-005 has a rapid onset effect of lowering hypertension followed by sustained release of the drug inside an animal body for at least 24 hours. Thus, the ASD-005 liposomal formulation avoids the rapid clearance that was experienced with an IV solution of the ASD-005 compound. Results suggest that the liposomal form of ASD-005 present an attractive sustained drug delivery for effective parenteral treatment of acute hypertension and congestive heart failure.

You can read the entire column on the [Drug Development & Delivery website](https://drug-dev.com/formulation-forum-parenteral-sustained-delivery-of-asd-005-liposomal-formulation-a-case-study-in-applications-of-lipid-based-nanoparticle-carriers/). You can also [contact us](https://ascendiapharma.com/contact/) to learn more and discuss how Ascendia can help with your drug development pipeline.

 

 

[View full post](https://ascendiacdmo.com/newsroom/2020/12/09/case-study-in-lipid-based-nanoparticle-carrier-applications)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Patrick Brightman"
  },
  "dateModified" : "2024-12-01T07:12:25.702Z",
  "datePublished" : "2020-12-09T05:00:00Z",
  "headline" : "Formulation Forum: Case Study in Lipid-based Nanoparticle Carrier Applications",
  "image" : {
    "@type" : "ImageObject",
    "height" : 191,
    "url" : "https://19566523.fs1.hubspotusercontent-na1.net/hubfs/19566523/Imported_Blog_Media/ascendia-ff1020-fig-2-2.jpg",
    "width" : 293
  },
  "mainEntityOfPage" : "https://ascendiacdmo.com/newsroom/2020/12/09/case-study-in-lipid-based-nanoparticle-carrier-applications",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Newsroom"
  }
}
```